H. Delesen

发表

Inhalation of a Dry Powder Ciprofloxacin Formulation in Healthy Subjects: A Phase I Study

Stefan Willmann, H. Stass, S. Willmann, 2013, Clinical Drug Investigation.

Safety and Pharmacokinetics of Sorafenib Combined With Capecitabine in Patients With Advanced Solid Tumors: Results of a Phase 1 Trial

C. Lathia, E. Brendel, A. Awada, 2011, Journal of clinical pharmacology.

Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.

H. Stass, D. Staab, J. Nagelschmitz, 2015, Journal of aerosol medicine and pulmonary drug delivery.

Pharmacokinetics and Tissue Penetration of Moxifloxacin in Intervention Therapy for Intra-Abdominal Abscess

H. Stass, D. Kubitza, H. Delesen, 2008, Clinical drug investigation.

Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis.

H. Stass, D. Kubitza, H. Delesen, 2006, The Journal of antimicrobial chemotherapy.

BAY 94‐9027, a PEGylated recombinant factor VIII, exhibits a prolonged half‐life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies

S. Lalezari, H. Delesen, T. Coyle, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Pharmacokinetic properties of BAY 81‐8973, a full‐length recombinant factor VIII

S. Garger, S. Lalezari, H. Delesen, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS

J. Windyga, S. Lalezari, U. Martinowitz, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction.

H. Stass, A. Halabi, D. Kubitza, 2002, British journal of clinical pharmacology.

Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200 mg oral itraconazole given once a day in healthy subjects.

H. Stass, J. Nagelschmitz, H. Delesen, 2004, International journal of clinical pharmacology and therapeutics.

Moxifloxacin does not Alter Ciclosporin Pharmacokinetics in Transplant Patients

I. Roots, H. Stass, D. Kubitza, 2012 .

Moxifloxacin does not alter ciclosporin pharmacokinetics in transplant patients: a multiple-dose, uncontrolled, single-centre study.

I. Roots, H. Stass, D. Kubitza, 2010, Clinical drug investigation.

Effects of Sucralfate on the Oral Bioavailability of Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, in Healthy Volunteers

H. Stass, J. Möller, H. Delesen, 2001, Clinical Pharmacokinetics.

Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males.

H. Stass, J. Möller, D. Kubitza, 2005, British journal of clinical pharmacology.

Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer

M. Büchert, D. Strumberg, M. Scheulen, 2011, Vascular cell.

Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.

H. Stass, J. Nagelschmitz, H. Delesen, 2015, Journal of aerosol medicine and pulmonary drug delivery.

Pharmacokinetics of ciprofloxacin PulmoSphere® inhalational powder

H. Stass, S. Willmann, D. Staab, 2008 .